---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000090"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:35:08.144194+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023

## Summary
- Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.
- R&D expenses rose to $50.6M (from $28.4M) driven by IMVT-1402 development and batoclimab milestones.
- IMVT-1402 Phase 1 single-ascending dose data expected Sept 2023; multiple-ascending dose data Oct/Nov 2023.
- Batoclimab Phase 3 MG data H2 2024; Phase 3 TED data H1 2025; CIDP Phase 2b initial data H1 2024; GD proof-of-concept Q4 2023.
- Acquired IPR&D expenses $12.5M from batoclimab milestone achievement under HanAll agreement.

## SEC filing metadata
- accession: 0001764013-23-000090
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/0001764013-23-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/imvt-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000090
- JSON: https://secwatch.observer/filing/0001764013-23-000090.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000090.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported fiscal first quarter ended June 30, 2023 results: net income Net loss was $73.9 million ($0.57 per common share), EPS $0.57 per common share.
  - Period: fiscal first quarter ended June 30, 2023
  - Net income: Net loss was $73.9 million ($0.57 per common share)
  - EPS: $0.57 per common share
  - Result: reported results
  source text: Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/0001764013-23-000090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.